High-performance liquid chromatographic determination of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil and its metabolite (E)-5-(2-bromovinyl)uracil in serum.
A high-performance liquid chromatographic method was developed to assay 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil and its metabolite (E)-5-(2-bromovinyl)uracil in serum. The chloro analogue of the parent drug is used as internal standard. Human serum samples were assayed to establish the pharmacokinetic parameters. Acetonitrile, used as a protein precipitant, was evaporated to dryness and the residue, containing the analytes and internal reference, was dissolved in mobile phase prior to chromatographic analysis. The minimum quantifiable level was 0.02 micrograms of each analyte per ml of serum.
Whigan
D B
DB
Department of Metabolism and Pharmacokinetics, Bristol-Meyers Squibb Pharmaceutical Research Institute, New Brunswick, NJ 08901.
Cohen
A I
AI
D000998:Antiviral Agents / Q000097:blood / Q000378:metabolism*; D001086:Arabinofuranosyluracil / Q000031:analogs & derivatives* / Q000097:blood / Q000378:metabolism; D002851:Chromatography, High Pressure Liquid; D006801:Humans; D015203:Reproducibility of Results; D013056:Spectrophotometry, Ultraviolet
D000998:Antiviral Agents; D001086:Arabinofuranosyluracil; C031368:sorivudine